

台灣胰臟醫學會&台灣神經內分泌腫瘤學會

2026 年度春季會

日期：2026 年 3 月 14 日 (星期六) 9:00~12:20

地點：台中福華大飯店 5 樓 CR501 會議室

地址：台中市西屯區安和路 129 號 5 樓

主辦單位：台灣胰臟醫學會、台灣神經內分泌腫瘤學會

報名費：會員免費；非會員 1,000 元 (現場繳納)

報到時間：8:30~

Time	Topic	Speaker	Moderator
9:00~9:05	Opening remarks	台灣胰臟醫學會 <u>石宜銘</u> 理事長 台灣神經內分泌腫瘤學會 <u>陳明晃</u> 理事長	
9:05~9:45	專題演講： Pituitary tumor: NET or NOT	<u>粘峯榕</u> 醫師 台大癌醫 內分泌科	<u>沈延盛</u> 醫師 成大 一般外科
9:45~10:25	專題演講： Escalating Somatostatin Analog Therapy in NET: Clinical Cases and Practical Considerations	<u>楊陽生</u> 醫師 中榮 腫瘤醫學部	<u>白禮源</u> 醫師 中國附醫 血液腫瘤科
10:25~10:40	Coffee break		
10:40~11:20	專題演講： Pancreatic Cancer Treatment in Asia: Optimizing the Role of TS-1 in Real-World Practice	<u>林欣辰</u> 醫師 中榮 腫瘤醫學部	<u>陳明晃</u> 醫師 北榮 腫瘤醫學部
CASE 1 : 11:20~11:40 11:40~11:50	病例報告 綜合討論	<u>葉宗讓</u> 醫師 高醫 血液腫瘤內科	<u>陳立宗</u> 醫師 高醫 內科 <u>葉大森</u> 醫師 林口長庚 一般外科
CASE 2 : 11:50~12:10 12:10~12:20	病例報告 綜合討論	<u>石柏威</u> 醫師 台北榮總 一般外科	<u>王心儀</u> 醫師 北榮 一般外科 <u>陳仁熙</u> 醫師 林口長庚 腫瘤科
12:30~	台灣胰臟醫學會&台灣神經內分泌腫瘤學會 理監事會議		

學會教育積分：(申請中)

台灣外科醫學會、台灣消化系外科醫學會、台灣內視鏡外科醫學會、台灣內科醫學會、台灣消化系醫學會、台灣消化系內視鏡醫學會、中華民國醫用超音波醫學會、中華民國癌症醫學會、中華民國內分泌學會、中華民國核醫學學會

粘峯榕 醫師

學歷

國立成功大學醫學系學士

國立台灣大學臨床醫學研究所碩士

經歷

2008~2013 台大醫院內科部住院醫師

2011~2013 台大醫院內分泌暨新陳代謝科研修醫師

2013~2021 台大醫院雲林分院內分泌暨新陳代謝科主治醫師

2016~2021 台大醫院雲林分院糖尿病中心主任

參與學術團體

中華民國內科醫學會會員

中華民國糖尿病學會會員

中華民國內分泌學會會員

現職

2021~ 迄今 台大醫院癌醫分院綜合內科部內分泌科主治醫師

2013~ 迄今 台大醫院內科部兼任主治醫師

學術專長

腦下垂體、甲狀腺、腎上腺、性腺等內分泌疾病;肥胖、代謝症候群、糖尿病、高血壓、高血脂、膽固醇異常等新陳代謝疾病之診斷及治療、甲狀腺超音波暨超音波細針穿刺檢查



CURRICULUM VITAE (簡歷)

楊陽生醫師

訓練經歷： 台中榮民總醫院內科部 住院醫師、總醫師
台中榮民總醫院內科部 血液腫瘤科主治醫師
台中榮民總醫院癌症防治中心 副主任
台中榮民總醫院腫瘤醫學中心 副主任
台中榮民總醫院腫瘤醫學部 主治醫師/科主任

現職： 台中榮民總醫院 腫瘤醫學部 主治醫師/科主任 (癌症防治科)

學歷： 中國醫藥大學 醫學系畢業

連絡方式：

電子郵件: ysyang003175@yahoo.com.tw

聯絡電話: 04-23592525 轉 3181

地址: 407219 台中市西屯區臺灣大道四段 1650 號

台中榮民總醫院 腫瘤醫學部

專科及次專科簡歷：

癌症醫學會	腫瘤內科專科醫師、腫瘤內科專科指導醫師
乳房醫學會	乳房專科醫師
內科醫學會	內科專科醫師、內科專科指導醫師
血液病學會	血液病專科醫師、血液病專科指導醫師
血液及骨髓移植學會	血液及骨髓移植專科醫師、血液及骨髓移植專科指導醫師
癌症安寧緩和醫學會	癌症安寧緩和專科醫師

專長及興趣領域：

1. 固態腫瘤

NET (Neuroendocrine tumor)	神經內分泌腫瘤
GIST (Gastrointestinal stromal tumor)	胃腸道基質瘤
Breast cancer	乳癌
Melanoma & Immuno-Oncology	惡性黑色素瘤與免疫療法
Sarcoma/Osteogenic sarcoma	惡性軟組織肉瘤與骨肉瘤
Gastric, Pancreatic, Biliary tract cancers	胃、膽、胰癌

2. 血液病相關癌症

Multiple myeloma	多發性骨髓瘤
CML (Chronic myeloid leukemia)	慢性骨髓性白血病
Lymphoma / CAR-T therapy	惡性淋巴瘤
CLL (Chronic lymphocytic leukemia)	慢性淋巴球性白血病
MPN (Myeloproliferative neoplasm)	骨髓增生性疾病

癌症相關院內職務：

台中榮民總醫院 腫瘤醫學部主治醫師 / 癌症防治科科主任

台中榮民總醫院 癌症專科團隊成員：

皮膚癌團隊(含惡性黑色素瘤)、

肢體肉瘤團隊、

乳癌團隊、

血液腫瘤團隊

癌症診療相關院外職務：

國民健康署 癌症診療品質認證委員

台灣神經內分泌腫瘤學會 監事

版本: 2026/01/30

Curriculum vitae

姓名: 林欣辰

出生年月日: 1986.5.15

性別: 男

電話: 0933-180445

E-mail: jawlin15@hotmail.com

現職:

台中榮民總醫院腫瘤內科主治醫師

學歷及證照:

2004~2011: 中國醫藥大學醫學系 (學士)

2011: 醫師執照

2015: 內科專科醫師執照

2017: 血液病專科醫師執照

2018: 腫瘤內科專科醫師執照

2018: 中華民國實驗室認證基金會 (TAF) 醫學實驗室認證訓練課程進修

2019: 臺灣安寧緩和醫學學會醫師

經歷:

2011~2012: 台中榮民總醫院不分科住院醫師

2012~2015: 台中榮民總醫院內科住院醫師

2015~2017: 台中榮民總醫院血液腫瘤科總醫師

2017~2019: 台中榮民總醫院血液腫瘤科代理主治醫師暨科實驗室主管

2019~2021: 台中榮民總醫院嘉義分院血液腫瘤科主治醫師 (任編整合癌症治療中心主任)

2021~ : 台中榮民總醫院血液腫瘤科主治醫師

論文:

1. Chou IC, Wang CS, Lin WD, **Lin HC**, Tsai CH, Wang TR, Tsai FJ.

Holocarboxylase synthetase deficiency: report of one case.

Acta Paediatr Taiwan. 2006 Nov-Dec;47(6):309-11.

2. **Lin HC**, Han SM, Hwang WL, Chou CW, Chang KH, Shi ZY, Teng CL.

Cytomegalovirus infection and treatment in allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution in an endemic area.

Turk J Haematol. 2017 Jun; 34(2): 159–166.

3. **Lin HC**, Chou CW.
Recurrent malignant phyllodes tumor of breast with gastric metastasis.
J Cancer Res Pract 2019;6:132-5
4. Hung CC, Tsai IC, Hsu CY, **Lin HC**.
Clinical Outcomes of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients: A Single-Center Retrospective Study.
J Clin Med. 2022 Mar 5;11(5):1434.
5. Liao PW, Cheng SB, Chou CW, **Lin HC**, Lin CH, Chen TC, Hsu CY, Teng CL, Shih YH.
Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study.
Clin Med Insights Oncol. 2022 Sep
6. Li PH, **Lin HC**
Frontline Autologous Stem Cell Transplantation in POEMS Syndrome with Pulmonary Arterial Hypertension
J Cancer Res Pract 2023;10:34-7
7. **Lin HC**, Shih YH
Adjuvant Gemcitabine+S1 for resected pancreatic cancer: a real-world experience in single center retrospective study
Poster, ASCO GI 2023
8. Shih YH, **Lin HC**, Liao PW, Chou CW, Lin CH, Hsu CY, Teng CJ, Wu FH, Luo SC, Kao SH.
The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
BMC Cancer. 2023 Aug 18;23(1):770.
9. Su YY, Chiang NJ, Chiu TJ, Huang CJ, Hsu SJ, **Lin HC**, Yang SH, Yang Y, Chou WC, Chen YY, Bai LY, Li CP, Chen JS.
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
Biomed J. 2024 Jun;47(3):100696.
10. Tseng KY, Hsu CY, Shih YH, **Lin HC**, Li YC, Jerry Teng CL, Chou CW.
The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center
Ther Adv Med Oncol. 2024 May 6:16:17588359241247019
11. Liao PW, Lu HJ, Chen TC, **Lin HC**, Shih YH, Teng CJ.
The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step-up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study.
Cancer Rep (Hoboken). 2024 May;7(5):e2102. doi: 10.1002/cnr2.2102.

12. Wu CH, Lai CL, Hsu YC, Hsu CY, Wang YC, **Lin HC**.

Pre-treatment pan-immune-inflammation value as a prognostic marker of pazopanib in soft tissue sarcoma.

Ther Adv Med Oncol. 2024 Oct 28;16:17588359241292255

13. Tseng KY, Chen YJ, Hsu CY, Shih YH, **Lin HC**.

The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study.

BMC Cancer. 2025 Jul 22;25(1):1200.

14. Tsai YC, **Lin HC**, Hsu CY, Wu FH, Luo SC, Shih YH

Lymph Node Ratio as a Risk Factor for Early Recurrence in Older Patients with Stage II/III Gastric Cancer: A Retrospective Study

J Clin Med. 2025 Sep 19;14(18):6609

15. **Lin HC**, Tseng KY, Shih YH.

Real-world effectiveness of durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in advanced gallbladder cancer: a study using the TriNetX global network

Ther Adv Med Oncol. 2025 Nov 7:17:17588359251393064.

Curriculum Vitae

Tsung-Jang Yeh (葉宗讓) M.D.



PERSONAL INFO

Current position:

Assistant Professor, School of Post Baccalaureate Medicine, College of Medical, Kaohsiung Medical University

Attending Physician, Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital

Nationality: Taiwan

Address: No. 100, Tz-You 1st Rd, Kaohsiung City 807, Taiwan

Tel.: +886-7-312-1101 ext. 6109

Fax: +886-7-316-2429

E-mail: aw7719@gmail.com

EDUCATION

School of Medicine, Kaohsiung Medical University	2006.09~2013.06
Master of Medicine, Graduate Institute of Clinical Medicine, Kaohsiung Medical University	2019.09~2022.01
Doctoral degree, Graduate Institute of Clinical Medicine, Kaohsiung Medical University	2023.09~

PROFESSIONAL EXPERIENCE

Internship, Kaohsiung Medical University Hospital	2012.06~2013.05
Post-graduate year training, Kaohsiung Medical University Hospital	2014.08~2015.07
Resident, Department of Internal Medicine, Kaohsiung Medical University Hospital	2015.08~2018.07
Fellowship, Division of Hematology and Oncology, Kaohsiung Medical University Hospital	2018.08~2020.07
Attending physician, Division of Hematology and Oncology, Kaohsiung Medical University Hospital	2020.08~present
Short term Research Fellow, Department of Regenerative Medicine, Kanazawa Medical University, Kanazawa, Japan	2023.10~12
Clinical Assistant Professor, College of Medicine, Kaohsiung Medical University	2024.08~present

BOARD CERTIFICATION

Board examination of Taiwan Society of Cancer Palliative Medicine	2022
Board examination of Medical Oncology, Taiwan	2021
Board examination of Hematology, Taiwan	2020
Board examination of Blood and Marrow Transplantation, Taiwan	2020
Board examination of Internal Medicine, Taiwan	2018
Taiwan Medical License	2013

ACADEMIC MEMBERSHIPS

Formosan Medical Association
Taiwan Society of Internal Medicine
The Hematology Society of Taiwan
Taiwan Society of Blood and Marrow Transplantation
Taiwan Oncology Society
Taiwan Clinical Oncology Society
Taiwan Society of Cancer Palliative Medicine

AWARDS

✓ Kaohsiung Medical University, Department of Internal Medicine, Best Intern Award	2012
✓ Kaohsiung Medical University, Excellent Evidence-Based Medicine Award in Interns	2012
✓ International Congress of BMT (ICBMT) 2018, Travel Award, Korea	2018
✓ Kaohsiung Medical University, Department of Internal Medicine, Best Chief Resident Award	2019
✓ 2020 Highlight of ASH in Asia, Vietnam, Travel Grants	2020
✓ International Congress of BMT (ICBMT) 2021, Poster Presentation Award, Korea	2021
✓ Taiwan Society of Blood and Marrow Transplantation, 1 st TBMT Academy Class, Training Qualification	2021
✓ International Congress of BMT (ICBMT) 2022, Overseas Contribution Award (Poster), Korea	2022
✓ ESMO Asia 2022, Singapore, Travel Grants	2022
✓ Center for Drug Evaluation, Taiwan, "Enhanced Early Clinical Trial Energy Program" Training Qualification	2022
✓ International Congress of BMT (ICBMT) 2024, Travel Award, Korea	2024

PUBLICATIONS

1. **Yeh TJ**, Wang HC, Cho SF, Wu CC, Hsieh TY, Huang CT, Wang MH, Chuang TM, Gau YC, Du JS, Liu YC, Hsiao HH, Pan MR, Chen LT, Moi SH. The Prognosis Performance of a Neutrophil- and Lymphocyte-Associated Gene Mutation Score in a Head and Neck Cancer Cohort. *Biomedicines*. 2023 Nov 22;11(12):3113.
2. **Yeh TJ**, Luo CW, Du JS, Huang CT, Wang MH, Chuang TM, Gau YC, Cho SF, Liu YC, Hsiao HH, Chen LT, Pan MR, Wang HC, Moi SH. Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer. *Biomedicines*. 2023 Feb 24;11(3):691.
3. **Yeh TJ**, Yang CI, Huang CT, Wang MH, Chuang TM, Ke YL, Gau YC, Du JS, Wang HC, Cho SF, Lee CP, Hsu CM, Hsiao HH, Liu YC. Revisit of the Association between Cytomegalovirus Infection and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World Analysis from a High CMV Seroprevalence Area. *J Fungi (Basel)*. 2022 Apr 16;8(4):408.
4. **Yeh TJ**, Chan LP, Tsai HT, Hsu CM, Cho SF, Pan MR, Liu YC, Huang CJ, Wu CW, Du JS, Wang HC. The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience. *Biology (Basel)*. 2021 Feb 23;10(2):168.
5. **Tsung-Jang Yeh**, Shih-Hao Tang, Yi-Chang Liu, Hui-Hua Hsiao. Primary Adenocarcinoma of the Urinary Bladder: Report of Two Cases with a Literature Review. *J Cancer Res Pract* 2020;7:130-3.
6. **Yeh TJ**, Yeh CJ, Liu YC, Hsiao HH. Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma. *Transfusion*. 2019 Aug;59(8):2751-2752.
7. Cho SF, **Yeh TJ**, Wang HC, Du JS, Gau YC, Lin YY, Chuang TM, Liu YC, Hsiao HH, Moi SH. Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphoma. *Sci Rep*. 2024 Mar 14;14(1):6161.
8. Cho SF, **Yeh TJ**, Anderson KC, Tai YT. Bispecific antibodies in multiple myeloma treatment: A journey in progress. *Front Oncol*. 2022 Oct 18;12:1032775.
9. Gau YC, **Yeh TJ**, Hsu CM, Hsiao SY, Hsiao HH. Pathogenesis and Treatment of Myeloma-Related Bone Disease. *Int J Mol Sci*. 2022 Mar 14;23(6):3112.
10. Wang HC, **Yeh TJ**, Chan LP, Hsu CM, Cho SF. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. *Int J Mol Sci*. 2020 Oct 15;21(20):7621. doi: 10.3390/ijms21207621.
11. Hsu CM, Kao SY, Yen CH, Hsiao CE, Cho SF, Wang HC, **Yeh TJ**, Du JS, Wang MH, Hsieh TY, Hsiao SY, Tsai Y, Hung LC, Liu YC, Chang KC, Hsiao HH. Biomarker potential of nuclear Nrf2 activation in the ABC subtype of diffuse large B-cell lymphoma. *Oncol Lett*. 2024 Oct 25;29(1):30.
12. Hsiao HH, Liu YC, Wang HC, Du JS, Tang SH, **Yeh TJ**, Hsieh CY, Gau YC, Ke YL, Chuang TM, Hsiao CE, Yen CH, Cho SF, Hsiao SY, Chiou SS, Lin SY, Hsu CM, Lu PL. Comparison of a novel lateral-flow device to galactomannan assay at different time periods for detections of invasive aspergillosis. *J Formos Med Assoc*. 2022 Oct;121(10):2123-2129.
13. Hsu CM, Yen CH, Wang SC, Liu YC, Huang CT, Wang MH, Chuang TM, Ke YL, **Yeh TJ**, Gau YC, Du JS, Wang HC, Cho SF, Tsai Y, Hsiao CE, Hsiao SY, Hsiao HH. Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy. *Biomedicines*. 2022 Jul 8;10(7):1638.
14. Du JS, Kuo YC, Shi HY, Wang MC, Wang LY, Chuang TM, Ke YL, **Yeh TJ**, Gau YC, Wang HC, Cho

- SF, Hsiao SY, Liu YC, Hsu CM, Hsiao HH. The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan. *J Pers Med*. 2022 Jan 19;12(2):130.
15. Hsiao HH, Yeh CJ, Ting SC, Chuang TM, Ke YL, **Yeh TJ**, Gau YC, Du JS, Hsiao CE, Wang HC, Cho SF, Hsu CM, Liu YC. Is it reasonable for the use of Rh-ee blood? A hospital-based survey from a southern medical center in Taiwan. *Kaohsiung J Med Sci*. 2022 Jan;38(1):65-69.
 16. Chuang TM, Liu YC, Hsiao HH, Wang HC, Du JS, **Yeh TJ**, Gau YC, Ke YL, Yang CI, Lee CP, Hsu CM, Cho SF. Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study. *Nutrients*. 2021 Sep 17;13(9):3243.
 17. Tsai YF, Liu YC, Yang CI, Chuang TM, Ke YL, **Yeh TJ**, Gau YC, Du JS, Wang HC, Cho SF, Hsu CM, Wu PF, Huang CI, Huang CF, Yu ML, Dai CY, Hsiao HH. Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection. *J Pers Med*. 2021 Aug 27;11(9):844.
 18. Wang HC, Hsiao HH, Du JS, Cho SF, **Yeh TJ**, Gau YC, Liu YC, Moi SH. Effect of Tumor Microenvironment and Angiogenesis on Clinical Outcomes of Primary Central Nervous System Lymphoma. *Biomed Res Int*. 2021 Sep 30;2021:3291762.
 19. Gau YC, Hsiao HH, Liu YC, **Yeh TJ**. Case report of coexistence of myeloproliferative neoplasms and multiple myeloma. *Kaohsiung J Med Sci*. 2020 Jun;36(6):469-470.
 20. Liu YC, Lee CP, **Yeh TJ**, Gau YC, Hsieh CY, Ke YL, Du JS, Lin MH, Wang HC, Tang SH, Cho SF, Hsiao CE, Hsu JF, Hsiao SY, Hsu CM, Hsiao HH. Calreticulin Mutation Survey by High Resolution Melting Method Associated with Unique Presentations in Essential Thrombocythemic Patients. *Mediterr J Hematol Infect Dis*. 2020 May 1;12(1):e2020022. (IF: 1.6)
 21. Wang HC, Liu PL, Lo PC, Chang YT, Chan LP, **Yeh TJ**, Hsiao HH, Cho SF. Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study. *PeerJ*. 2020 Sep 10;8:e9862.

石柏威 醫師

Bor-Uei Shyr, MD.



學歷 中山醫學大學醫學系 醫學士

經歷 現職:

- 2019年迄今臺北榮總外科部一般外科 主治醫師

- 2023 年迄今國立陽明大學外科 助理教授

經歷:

- 臺北榮總外科部移植外科臨床研究員

- 臺北榮總外科部移植外科住院總醫師

- 臺北榮總外科部住院醫師

醫療專長

達文西機械手臂胰臟及肝臟手術、腹腔鏡微創手術(肝膽胰、胃腸消化道、疝氣手術)、胰臟手術、肝臟手術、膽囊手術、胰腎移植手術、腹部急症手術、胃腸消化道手術、疝氣手術、甲狀腺手術、乳房手術

證照

外科專科醫師、消化外科專科醫師、達文西機械手臂胰臟手術認證資格、達文西機械手臂肝臟手術認證資格、胰臟移植醫師資格

著作

1. **Bor-Uei Shyr**, Shih-Chin Chen, Yi-Ming Shyr, Rheun-Chuan Lee, Shin-E Wang. Metastatic Polyp of the Gallbladder from Renal Cell carcinoma. BMC Cancer. 2017 Apr 4;17(1):244.
2. **Bor-Uei Shyr**, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Learning Curves for Robotic Pancreatic Surgery- from Distal Pancreatectomy to Pancreaticoduodenectomy. Medicine (Baltimore). 2018 Nov;97(45):e13000.
3. **Bor-Uei Shyr**, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Surgical, Survival, and Oncological Outcomes after Vascular Resection in Robotic and Open Pancreaticoduodenectomy. Surg Endosc 2020; 34 (1): 377-383.

4. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, I-Wen Chang, Yi-Ming Shyr, Shin-E Wang. Operative Results and Patient Satisfaction after Robotic Pancreaticoduodenectomy. *Asian J Surg* 2020; 43: 519-525.
5. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Chyle Leakage after Robotic and Open Pancreaticoduodenectomy. *J Hepatobiliary Pancreat Sci.* 2020; 27:273-279
6. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Mesopancreas level 3 dissection in robotic pancreaticoduodenectomy. *Surgery.* 2021; 169:362-368.
7. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma with robotic and open pancreatoduodenectomy. *Surg Endosc.* 2021 Mar 26.
8. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, Shih-Ching Chang, Yi-Ming Shyr, Shin-E Wang. Circulating cell-free DNA in resectable ampullary cancer. *Cancers (Basel)* 2021, 13, 2313.
9. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Robotic and open pancreaticoduodenectomy: results from Taipei Veterans General Hospital in Taiwan. *Updates in Surgery (UPIS)* 2021; 73:939–946
10. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Inferior survival outcomes of pancreas transplant alone in uremic patients. *Sci Rep* 11, 21073 (2021).
11. **Bor-Uei Shyr**, Bor-Shiuan Shyr, Shih-Chin Chen, Yi-Ming Shyr, Shin-E Wang. Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma with robotic and open pancreatoduodenectomy. *Surg Endosc.* 2022 Feb;36(2):1507-1514.
12. **Bor-Uei Shyr**, Yi-Ting Yeh, Wei-Nung Teng, Chin-Su Liu, Paul Chih-Hsueh Chen, Ling-Ju Huang, Ling-Ming Tseng, Hsu Ma. Minimally Required Personal Protective

Equipment During Local Anesthesia Surgeries in COVID-19: A Simulation Study. *Plast Reconstr Surg Glob Open*. 2023 Jan 18;11(1):e4792

13. **Shyr, B.-U.**, Shyr, B.-S., Chen, S.-C., Wang, S.-E. and Shyr, Y.-M. Impact of Obesity on Perioperative Outcomes in Robotic Pancreaticoduodenectomy: A Propensity Score-Matched Study. *Int J Med Robot*, 2024 Dec;20(6):e70034.
14. **Shyr BU**, Shyr BS, Shih MS, Chen SC, Wang SE, Shyr YM. Combined robotic/open pancreaticoduodenectomy in the young aged < 50 years. *Updates Surg*. 2025 Jan 15. doi: 10.1007/s13304-025-02082-8. Epub ahead of print.